Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
HSPPC-96 or Oncophage · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| HSPPC-96 or Oncophage | DRUG | - |
Eligibility Assessment: (The following assessments must be obtained within three weeks prior to randomization into the study) * Medical history and physical examination (including EGOG score, evidence of immunosuppression); * CT/MRI of the chest, abdomen and pelvis; * Clinical examination; * CT/MR...
HSPPC-96, also known as Oncophage, is an investigational small molecule being studied for the treatment of malignant melanoma. It is a heat shock protein-peptide complex that is being evaluated in patients with stage IV melanoma. The drug is still in clinical development and has not been approved by regulatory authorities.
HSPPC-96, or Oncophage, is a heat shock protein-peptide complex. It is designed to stimulate the immune system to recognize and attack cancer cells by presenting tumor-specific peptides to immune cells. This mechanism is intended to generate an anti-tumor immune response in patients with malignant melanoma.
HSPPC-96, also known as Oncophage, is being developed by Agenus Inc., a biopharmaceutical company. Agenus is listed on the stock exchange under the ticker symbol AGEN. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with malignant melanoma.
HSPPC-96, also known as Oncophage, is in Phase 3 clinical development. It is an investigational drug being studied for the treatment of malignant melanoma. The drug has not been approved by the FDA or other regulatory agencies and remains in clinical trials to assess its safety and effectiveness.
HSPPC-96, also known as Oncophage, has one completed Phase 3 clinical trial with the identifier NCT00039000. This trial studied the drug versus IL-2/DTIC for stage IV melanoma and enrolled 350 participants across multiple countries, including the United States, Australia, and several European nations. The trial was randomized but not double-blinded.
Yes, HSPPC-96 and Oncophage refer to the same drug. HSPPC-96 is the chemical name, while Oncophage is the brand name used by the developer, Agenus Inc. Both names are used interchangeably in clinical research and publications related to the treatment of malignant melanoma.